SCARB1 and prostate carcinoma: It has been proven that SR-BI functions as an oncogene and is over-expressed in a range of cancers, including nasopharyngeal carcinoma [32], prostate cancer [26, 33], breast cancer [34–37], adrenocortical cancer [38].